Previous 10 | Next 10 |
Recognizes Exemplary Board Practices Related to DE&I AtriCure Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that i...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will present at the 34th Annual Piper Sandler Healthcare Confe...
AtriCure, Inc. (ATRC) Q3 2022 Earnings Conference Call November 1, 2022 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Particip...
AtriCure press release ( NASDAQ: ATRC ): Q3 GAAP EPS of -$0.27 misses by $0.02 . Revenue of $83.2M (+18.1% Y/Y) beats by $1.88M . 2022 Financial Guidance Full year 2022 revenue is projected to be approximately $328 million to $333 million vs $328.61M consen...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2022 financial results. “We are proud to ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2022 financial results on ...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will host an investor education webcast at 2:00 p.m. Eastern T...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Morgan Stanley 20 th ...
AtriCure, Inc. (ATRC) Q2 2022 Earnings Conference Call August 2, 2022 16:30 ET Company Participants Marissa Bych - Investor Relations Mike Carrel - President and Chief Executive Officer Angie Wirick - Chief Financial Officer Conference Call Participants ...
AtriCure press release ( NASDAQ: ATRC ): Q2 GAAP EPS of -$0.32 misses by $0.03 . Revenue of $84.53M (+18.4% Y/Y) beats by $4.86M . Full year 2022 revenue is projected to be approximately $323 million to $333 million, reflecting growth of approximately 18% to 21...
News, Short Squeeze, Breakout and More Instantly...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received regulatory approval from the National Medical Products A...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter 2024 financial results on Tuesday, Ju...